Renestetika - Company finances
|
EUR
|
2019
From: 2019-02-05
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 241,357 | 206,521 | 219,515 | 374,793 | 169,457 | 103,972 | 138,062 |
| Profit before tax | - | - | - | - | - | - | - |
| Net profit | 25,866 | 24,397 | 36,037 | 95,955 | -2,414 | 2,178 | 7,389 |
| Equity | 28,366 | 9,124 | 45,161 | 99,116 | 96,702 | 98,880 | 106,268 |
| Liabilities | 56,984 | 37,604 | 155,845 | 52,106 | 9,213 | 4,146 | 6,068 |
| Non-current assets | 1,231 | 895 | 81,614 | 3,155 | 9,272 | 6,891 | 5,806 |
| Current assets | 84,119 | 45,833 | 119,392 | 148,067 | 96,643 | 96,135 | 106,530 |
| Total assets | 85,350 | 46,728 | 201,006 | 151,222 | 105,915 | 103,026 | 112,336 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 36,728 | 4,686 | 7,791 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | -14.4% | +6.3% | +70.7% | -54.8% | -38.6% | +32.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 30.3% | 52.2% | 17.9% | 63.5% | -2.3% | 2.1% | 6.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 91.2% | 267.4% | 79.8% | 96.8% | -2.5% | 2.2% | 7.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 10.7% | 11.8% | 16.4% | 25.6% | -1.4% | 2.1% | 5.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.0 | 4.1 | 3.5 | 0.5 | 0.1 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 221,246 | 103,261 | 109,758 | 187,397 | 84,729 | 56,713 | 138,062 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Renestetika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-06-17 | 2025-07-03 | 0.49 |
| 2025-05-16 | 2025-06-04 | 0.49 |
| 2025-05-04 | 2025-05-04 | 0.49 |
| 2025-04-24 | 2025-04-29 | 0.49 |
| 2025-01-16 | 2025-01-22 | 224.76 |
Renestetika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-04 | 2025-04-04 | 186.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Renestetika, UAB (code 305012098) is a private limited liability company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €138.1K and net profit of €7.4K, corresponding to a profit margin of 5.4%. Revenue increased by 32.8% year on year, showing a clear recovery after 2024, when turnover was €104.0K and net profit €2.2K. In 2023, revenue was higher at €169.5K, but the company posted a loss of €2.4K, so profitability improved steadily over the three-year period. The balance sheet remained compact and conservative in 2025, with total assets of €112.3K, equity of €106.3K and liabilities of €6.1K. Equity represented 94.6% of assets, and debt-to-equity was 0.06, indicating low leverage. Return on equity was 7.0% and return on assets 6.6%, while asset turnover stood at 1.23x. Revenue per employee was €138.1K and profit per employee €7.4K in 2025.